XBiotech Inc.

XBIT Healthcare Biotechnology

XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million. In the quarter to June 2026, EPS fell 266.7% and free cash flow grew 25.3%, each against the same quarter a year earlier.

2.12 0.04 −1.85%
Market cap
$65.9M
P/E
0.0×
Fwd P/E
−3.3×
Dividend yield
—
F-score
3/9
Altman Z
11.69
Beneish M
−4.17
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
41.78 16.01 39.03 33.15
Net Debt/EBITDA
26.22 4.27 19.43 18.74
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.14) (0.75) (0.29) (0.15)
Book value per Share
5.48 4.60 4.43 4.21
Free Cash Flow
(4.37) (22.99) (8.97) (4.51)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates